Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biomaterials

• Publication date

  2005-02-01

• Fields of study

  Medicine, Materials Science, Engineering

• Identifiers
  DOI 10.1016/J.BIOMATERIALS.2004.02.040PMID 15275819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.

  2003cited by this paper
• Impact of transport and drug properties on the local pharmacology of drug-eluting stents

  2003cited by this paper
• Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience.

  2003cited by this paper
• Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles.

  2002cited by this paper
• Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics.

  2002cited by this paper
• New tools for prevention of restenosis could decrease the "oculo-stento" reflex.

  2002cited by this paper
• Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation.

  2002cited by this paper
• Macrophage Depletion by Clodronate-Containing Liposomes Reduces Neointimal Formation After Balloon Injury in Rats and Rabbits

  2002cited by this paper
• Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel

  2002cited by this paper
• Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery

  2002cited by this paper
• Formulation and Delivery Mode Affect Disposition and Activity of Tyrphostin-Loaded Nanoparticles in the Rat Carotid Model

  2001cited by this paper
• Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats.

  2000cited by this paper
• Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis.

  2000cited by this paper
• Protein tyrosine kinase inhibitors as novel therapeutic agents.

  1999cited by this paper
• Protein phosphorylation and signal transduction.

  1999cited by this paper
• PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine.

  1998cited by this paper
• Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model.

  1998cited by this paper
• Arterial uptake of biodegradable nanoparticles: effect of surface modifications.

  1998cited by this paper
• Catheter-based drug delivery for restenosis

  1997cited by this paper
• The effect of intramural delivery of polymeric nanoparticles loaded with the antiproliferative 2-aminochromone U-86983 on neointimal hyperplasia development in balloon-injured porcine coronary arteries

  1997cited by this paper
• Modulation of growth factor action: implications for the treatment of cardiovascular diseases.

  1997cited by this paper
• Cell cycle regulation and control of angioplasty restenosis

  1997cited by this paper
• Nanoparticle drug delivery system for restenosis

  1997cited by this paper
• Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty.

  1996cited by this paper
• Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes.

  1995cited by this paper

• VSMCs in Atherosclerosis: Implications on the Role of Inflammation and Extracellular Matrix Remodelling.

  2025cites this paper
• Nanoparticle-based approaches for treating restenosis after vascular injury

  2024cites this paper
• Nanoparticles in Drug Delivery: From History to Therapeutic Applications

  2022cites this paper
• Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases

  2020cites this paper
• Nanoparticle Based Treatment for Cardiovascular Diseases.

  2019cites this paper
• Application of Light Scattering Techniques to Nanoparticle Characterization and Development

  2018cites this paper
• Physicochemical characteristics of liposomes are decisive for their antirestenosis efficacy following local delivery.

  2017cites this paper
• Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases

  2017cites this paper
• Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review.

  2017cites this paper
• Adequately-Sized Nanocarriers Allow Sustained Targeted Drug Delivery to Neointimal Lesions in Rat Arteries.

  2016cites this paper
• The use of polymer-based nanoparticles and nanostructured materials in treatment and diagnosis of cardiovascular diseases: Recent advances and emerging designs

  2016cites this paper
• Nanoparticulate Drug Delivery Systems

  2016cites this paper
• Targeting Therapies to Treat Vein Graft Disease and Restenosis

  2016cites this paper
• Nanotechnology in diagnosis and treatment of coronary artery disease.

  2016cites this paper
• Application of nanotechnology in device promotion in cardiology: A promising horizon for nanocardiology toward personalized medicine

  2015cites this paper
• Recent advances in micro/nanoscale biomedical implants.

  2014cites this paper
• Bioabsorbable Stent Quo Vadis: A Case for Nano-Theranostics

  2014cites this paper
• Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis

  2014cites this paper
• Nanomedicines for Restenosis Therapy

  2014cites this paper
• Role of biomaterials in prevention of in-stent restenosis.

  2014cites this paper
• Bioabsorbable Stent Quo Vadis: A Case for

  2014cites this paper
• Delivery of Polymeric Nanoparticles to Target Vascular Diseases.

  2014cites this paper
• Recent advances in drug eluting stents.

  2013cites this paper
• The Changing Face of Vascular Interventional Radiology: The Future Role of Pharmacotherapies and Molecular Imaging

  2013cites this paper
• Implant-associated local drug delivery systems based on biodegradable polymers: customized designs for different medical applications

  2013cites this paper
• Restenosis treatments using nanoparticle-based drug delivery systems.

  2013cites this paper
• Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes.

  2013cites this paper
• PEGylated estradiol benzoate liposomes as a potential local vascular delivery system for treatment of restenosis

  2012cites this paper
• Cardiovascular nanomedicine: Challenges and opportunities

  2012cites this paper
• Targeted Treatments for Restenosis and Vein Graft Disease

  2012cites this paper
• Nanomedicine in cardiovascular therapy: recent advancements

  2012cites this paper
• Nanoparticle-Mediated Local Delivery of an Antisense TGF-β1 Construct Inhibits Intimal Hyperplasia in Autogenous Vein Grafts in Rats

  2012cites this paper
• Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis.

  2011cites this paper
• Nanomedicine approaches in vascular disease: a review.

  2011cites this paper
• Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective

  2011cites this paper
• Biodegradable Sirolimus-loaded Poly(lactide) Nanoparticles as Drug Delivery System for the Prevention of In-Stent Restenosis in Coronary Stent Application

  2011cites this paper
• Nanobiotechnology in Cardiovascular Disorders

  2011cites this paper
• Coronary Angioplasty and Drug-Eluting Stents

  2011cites this paper
• Application Delivery System for the Prevention of In-Stent Restenosis in Coronary Biodegradable Sirolimus-loaded Poly ( lactide ) Nanoparticles as Drug

  2010cites this paper
• EMERGING APPLICATIONS OF NANOMEDICINE FOR THERAPY AND DIAGNOSIS OF CARDIOVASCULAR DISEASES

  2010cites this paper
• Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.

  2010cites this paper
• Stent-based release of a selective PDGF-receptor blocker from the bis-indolylmethanon class inhibits restenosis in the rabbit animal model.

  2010cites this paper
• On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study.

  2009cites this paper
• Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study

  2009cites this paper
• Local delivery of modified paclitaxel-loaded poly(epsilon-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia.

  2009cites this paper
• Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries

  2008cites this paper
• The Handbook of Nanomedicine

  2008cites this paper
• Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis.

  2008cites this paper
• Predicting In Vivo Efficacy of Potential Restenosis Therapies by Cell Culture Studies: Species-Dependent Susceptibility of Vascular Smooth Muscle Cells

  2008cites this paper
• Development of cardiovascular bypass grafts: endothelialization and applications of nanotechnology

  2008cites this paper
• Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats.

  2007cites this paper
• Nanotechnology in the diagnosis and management of heart, lung and blood diseases

  2007cites this paper
• MANUFACTURING AND NEAR-PHYSIOLOGICAL TESTING OF A BIODEGRADABLE METALLIC CORONARY STENT (BMCS)

  2007cites this paper
• Nano-Carriers of Drugs and Genes for the Treatment of Restenosis

  2007cites this paper
• Nanoparticulate carriers for the treatment of coronary restenosis

  2007cites this paper
• Erythropoietin Induces Excessive Neointima Formation: A Study in a Rat Carotid Artery Model of Vascular Injury

  2007cites this paper
• Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury.

  2007cites this paper
• Delivery of large biopharmaceuticals from cardiovascular stents: a review.

  2007cites this paper
• Modified Paclitaxel-loaded Nanoparticles for Inhibition of Hyperplasia in a Rabbit Arterial Balloon Injury Model

  2007cites this paper
• Nano- and microparticle-based imaging of cardiovascular interventions: overview.

  2007cites this paper
• Introduction to nanotechnology: potential applications in physical medicine and rehabilitation.

  2007cites this paper
• Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment.

  2007cites this paper
• New therapeutic possibilities for vein graft disease in the post-edifoligide era.

  2006cites this paper
• The promise of nanotechnology for heart, lung and blood diseases

  2006cites this paper
• Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies

  2006cites this paper
• PDGF receptor kinase inhibitors for the treatment of restenosis.

  2005cites this paper
• Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.

  2004cites this paper
• Introduction: signal transduction therapy-10 years later.

  2004cites this paper
• PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases.

  2004cites this paper